用抗FimA卵黄抗体 (IgYs) 进行被动免疫,可减轻小鼠Acinetobacter baumannii肺炎的发生
Nasibeh Shaygankho1, Abolfazl Jahangiri2, Iraj Rasooli3
1Department of Biology, Shahed University, Tehran, Iran.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|September 29, 2023
概括
蛋黄免疫球蛋白 (IgY) 针对FimA毒性因子,在小鼠中提供了对Acinetobacter baumannii肺炎的完整保护. 这为抗生素提供了一个有希望的,具有成本效益的替代品,用于对抗耐药性细菌感染.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 宝曼尼菌 (Acinetobacter baumannii) 是一种危险的病原体,引起严重的肺炎,死亡率高.
- 全耐药菌株使当前的抗生素无效,需要新的治疗策略.
- 蛋黄免疫球蛋白Y (IgY) 是一种潜在的经济有效的生物分子,用于被动免疫.
研究的目的:
- 评估蛋黄IgY针对FimA毒性因子的有效性,以对抗Acinetobacter baumannii肺炎的被动保护.
- 探索FimA作为产生保护性IgY抗体的向抗原.
主要方法:
- 重组FimA被生产并用于免疫母,从蛋黄产生特定的IgY抗体.
- 使用间接ELISA证实了抗FimAIgY的活性.
- 中性贫乏的小鼠在受到毒性A. baumannii分离的挑战之前,被内注射IgY.
主要成果:
- 特定的抗FimAIgY药物给药导致100%的抗A. baumannii感染的保护.
- 非特异性IgY延长了小鼠的生存时间,长达72小时,而对照小鼠在24小时内死亡.
- 与对照组相比,在接受抗FimA IgY治疗的小鼠中,肺部和脏中的细菌负载明显较低.
结论:
- FimA是一种可行的抗原,用于开发针对Acinetobacter baumannii的保护性IgY抗体.
- 蛋黄针对FimA的IgY显示出治疗A. baumannii感染的显著治疗潜力.
- 这种方法为耐药细菌病原体提供了一种具有成本效益和替代传统抗生素的替代策略.
更多相关视频
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
14.7K
05:40Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
Published on: April 25, 2025
752
相关概念视频
Active versus Passive Immunity
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Active Immunity
Active immunity refers to the resistance one develops...
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
